Is ruxolitinib cream (Opzelura) available in pharmacies in Hong Kong?

Ruxolitinib cream (Opzelura) has not yet received drug marketing approval in mainland China, so patients cannot purchase the drug through regular domestic channels. For patients who need to use ruxolitinib cream for treatment, they usually need to purchase it through overseas channels to ensure that the source of the drug is regular and the quality is reliable.

The availability of ruxolitinib cream is relatively limited in pharmacies in Hong Kong. Since the drug has not yet received widespread market authorization and circulation permission, some pharmacies in Hong Kong may not be able to provide the original version of ruxolitinib cream for the time being. If patients wish to purchase the drug in Hong Kong, it is recommended to consult the local pharmacy in advance to understand the specific inventory and drug purchase policies to avoid inconvenience.

In terms of price, the original version of ruxolitinib cream is produced by Incyte Company and sells for about 10,000 yuan, which is a high cost of treatment for most patients. At the same time, there are also imitation versions produced by Bangladesh Yaopin International on the market. The price is relatively affordable, only about 500 to 600 yuan, making it an economical choice for some patients. Regardless of whether they choose original drugs or generic drugs, patients should ensure that they purchase them through formal channels to ensure drug safety.

In general, the purchase channels for ruxolitinib cream in Hong Kong pharmacies are currently relatively limited. If patients need to use it, it is recommended to consult and prepare in advance. Combining price and purchase convenience, patients can choose the appropriate purchase channel and drug version according to their own conditions, and use the drug rationally under the guidance of professional doctors.

Reference materials:https://www.opzelura.com/